FMP
Dyne Therapeutics, Inc.
DYN
NASDAQ
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
24.47 USD
0.5 (2.04%)
About
ceo
Mr. John G. Cox M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.dyne-tx.comexchange
NASDAQ
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
CIK
0001818794
ISIN
US26818M1080
CUSIP
26818M108
Address
1560 Trapelo Road
Phone
781 786 8230
Country
US
Employee
173
IPO Date
Sep 17, 2020
Key Executives
